## Population 2017

		Rate
Estimates of TB burden*, 2017	Number (thousands)	(per 100 000 population)
Mortality (excludes HIV+TB)	0.037 (0.036-0.038)	4.1 (4-4.2)
Mortality (HIV+TB only)	<0.01 (<0.01-<0.01)	0.26 (0.18-0.36)
Incidence (includes HIV+TB)	0.45 (0.34-0.56)	49 (38–62)
Incidence (HIV+TB only)	0.012 (<0.01–0.016)	1.3 (0.82–1.8)
Incidence (MDR/RR-TB)**	<0.01 (<0.01-<0.01)	0.5 (0.28-0.77)

Estimated TB inci	stimated TB incidence by age and sex (thousands)*, 2017		
	0-14 years	> 14 years	Total
Females	0.023 (0.021-0.024)	0.15 (0.12-0.17)	0.17 (0.14-0.19)
Males	0.024 (0.023-0.026)	0.25 (0.21-0.3)	0.28 (0.22-0.33)
Total	0.047 (0.043-0.051)	0.4 (0.3–0.49)	0.45 (0.34-0.56)

TB case notifications, 2017		
Total cases notified		364
Total new and relapse		357
<ul> <li>% tested with rapid diagnostics at time of diagnosis</li> </ul>		83%
- % with known HIV status		92%
- % pulmonary		69%
- % bacteriologically confirmed among pulmonary		57%
Universal health coverage and social protection		
TB treatment coverage (notified/estimated incidence), 2017	80% (6	63–100)
TB patients facing catastrophic total costs, 2018		40%
TB case fatality ratio (estimated mortality/estimated incidence), 2017	0.09 (0.0	7–0.11)
TB/HIV care in new and relapse TB patients, 2017	Number	(%)
Patients with known HIV-status who are HIV-positive	9	3%
- on antiretroviral therapy	9	100%

		Previously treated	Total
Drug-resistant TB care, 2017	New cases	cases	number***
Estimated MDR/RR-TB cases among notified			6
pulmonary TB cases			(0–15)
Estimated % of TB cases with MDR/RR-TB	0% (0–2.6)	33% (0.84–91)	
% notified tested for rifampicin resistance	84%	16%	292
MDR/RR-TB cases tested for resistance to seco	nd-line drugs		1
Laboratory-confirmed cases		MDR/RR-TB: 1,	XDR-TB: 0
Patients started on treatment ****		MDR/RR-TB: 1,	XDR-TB: 0
Treatment success rate and cohort size		Success	Cohort
New and relapse cases registered in 2016		89%	296
Previously treated cases, excluding relapse, regis	stered in 2016	86%	14
HIV-positive TB cases registered in 2016		33%	6

	00/0	•
MDR/RR-TB cases started on second-line treatment in 2015		0
XDR-TB cases started on second-line treatment in 2015		0
TB preventive treatment, 2017		

% of HIV-positive people (newly enrolled in care) on preventive treatment % of children (aged < 5) household contacts of bacteriologically-confirmed > 100% TB cases on preventive treatment

TB financing, 2018

National TB budget (US\$ millions)

······································
Funding source: 51% domestic, 49% international, 0% unfunded


\* Ranges represent uncertainty intervals

\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin


\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed


# **Tuberculosis profile**




<1 million




Incidence (HIV+TB only)





### Treatment success rate (%)



#### New and relapse

<1

- Retreatment, excluding relapse
- HIV-positive MDR/RR-TB XDR-TB

### Total budget (US\$ millions)

